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Objectives:  Seniors  are  particularly  vulnerable  to complications  resulting  from  inﬂuenza  infection.  Numer-
ous  inﬂuenza  vaccines  are  available  to immunize  US  seniors,  and  practitioners  must  decide  which  product
to use.  Options  include  trivalent  and  quadrivalent  standard-dose  inactivated  inﬂuenza  vaccines  (IIV3  and
IIV4 respectively),  as  well  as  a  high-dose  IIV3  (HD).  Our  research  examines  the  public  health  impact,  bud-
get impact,  and  cost-utility  of HD  versus  IIV3  and IIV4  for immunization  of  US  seniors  65 years  of age  and
older.
Methods:  Our  model  was  based  on US inﬂuenza-related  health  outcome  data.  Health  care  costs and  vaccine
prices were  obtained  from  the  Centers  for  Medicare  and  Medicaid  Services.  Efﬁcacies  of  IIV3  and  IIV4
were  estimated  from  various  meta-analyses  of  IIV3  efﬁcacy.  The  results  of a head-to-head  randomized
controlled  trial  of HD  vs. IIV3  were  used  to  estimate  relative  efﬁcacy  of HD.  Conservatively,  herd protection
was  not  considered.
Results: Compared  to  IIV3,  HD  would  avert  195,958  cases  of  inﬂuenza,  22,567  inﬂuenza-related  hos-
pitalizations,  and  5423  inﬂuenza-related  deaths  among  US  seniors.  HD  generates  29,023  more  Quality
Adjusted  Life  Years  (QALYs)  and  a  net societal  budget  impact  of $154  million.  The  Incremental  Cost  Effec-
tiveness  Ratio  (ICER)  for  this  comparison  is  $5299/QALY.  71%  of  the  probabilistic  sensitivity  analysis  (PSA)
simulations  were  <$100,000/QALY.
Compared  to IIV4,  HD  would  avert  169,257  cases  of  inﬂuenza,  21,222  hospitalizations  and  5212  deaths.
HD  generates  27,718  more  QALYs  and a net societal  budget  impact  of −$17  million  and  as  such  dominates
IIV4.  For  this  comparison,  81%  of  PSA  simulations  were  <$100,000/QALY.
Conclusions:  HD  is  expected  to  achieve  signiﬁcant  reductions  in  inﬂuenza-related  morbidity  and  mortality.
Further,  HD  is a cost  effective  alternative  to  both  IIV3  and  IIV4  in  seniors.  Our  conclusions  were robust  in
the face  of sensitivity  analyses.
Publi© 2014  The  Authors.  
. Introduction
Seniors 65 years of age and older are particularly vulnerable to
omplications resulting from inﬂuenza infection. The US Centers
or Disease Control and Prevention (CDC) has consistently reported
igher inﬂuenza-related death and hospitalization rates amongst
eniors than in any other age group [1,2]. The heightened suscepti-
ility to complications is due in large part to natural and progressive
∗ Corresponding author at: Sanoﬁ Pasteur, 1755 Steeles Avenue West, Toronto,
ntario, Canada, M2R  3T4. Tel.: +1 647 406 0362.
E-mail address: Ayman.chit@sanoﬁpasteur.com (A. Chit).
ttp://dx.doi.org/10.1016/j.vaccine.2014.10.079
264-410X/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article unshed  by Elsevier  Ltd. This  is  an open  access  article  under  the  CC  BY-NC-SA
license  (http://creativecommons.org/licenses/by-nc-sa/3.0/).
weakening of the immune system over time. This phenomenon,
known as immunosenescence, also renders seniors less responsive
to vaccine [3]. This has led various manufacturers to develop vac-
cines designed speciﬁcally to elicit improved immune responses in
the elderly. One such vaccine, Fluzone® High-Dose (inﬂuenza virus
vaccine) (HD), was  licensed in the US in December 2009.
In addition, vaccine manufacturers recently have expanded the
number of viral strains in seasonal inﬂuenza vaccines to improve
coverage against circulating strains. Traditional inﬂuenza vaccines,
including HD, are trivalent and contain antigens from 3 viral
strains: A(H1N1), A(H3N2) and one of two co-circulating B lin-
eages, B(Victoria) or B(Yamagata). Each year, the US  Public Health
Service decides which viral strains should be included in the next
der the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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easonal inﬂuenza vaccine. However, accurately predicting which
-lineage strain will predominate in the upcoming season has
roven to be a challenging task resulting in frequent mismatches
ith the vaccine strain [4]. During mismatch seasons, efﬁcacy and
ffectiveness against the opposite B lineage have been reduced
5–11]. To address the issue of co-circulating B lineages, several
anufacturers have developed new seasonal inﬂuenza vaccines
hat include both inﬂuenza B virus strains. The US Food and Drug
dministration has approved 3 seasonal quadrivalent inﬂuenza
accines that can be administered to seniors: Fluarix® Quadrivalent
nd FluLaval® Quadrivalent vaccines distributed by GlaxoSmithK-
ine, and Fluzone® Quadrivalent vaccine distributed by Sanoﬁ
asteur.
Reed et al. [12] and Lee et al. [13], respectively evaluated the
elative public health and economic impact of IIV4 compared to
IV3 on the US population. The researchers concluded that IIV4
an offer a health and economic beneﬁt over IIV3 even if IIV4 was
riced at a moderate premium [13]. These studies, however, were
ot age stratiﬁed and it was not clear what the impact would
e on US seniors. Further, the analysis did not include HD as a
omparator. Today, the HD option cannot be overlooked given
he recent results from a head-to-head randomized controlled
rial (Sanoﬁ Pasteur study FIM12) [49]. This trial demonstrated
uperiority of HD compared to standard-dose Fluzone vaccine in
reventing laboratory-conﬁrmed inﬂuenza caused by any type
r sub-type associated with clinically relevant illness in person
65 years of age (relative efﬁcacy, 24.2% [95% CI 9.7–36.5%])
49].
A new public health and economic evaluation of vaccine options
or seniors should also consider other emerging data. Beyer and
olleagues [14] have recently published a meta-analysis estimat-
ng the vaccine effectiveness of IIV3 in senior populations. These
stimates were lower against serious complications than what was
ssumed in the analysis by Reed and colleagues. Moreover, Diaz-
ranados and colleagues [15], as well as Tricco and colleagues [16],
ecently have shown that IIV3 provides cross-protection during
nﬂuenza B mismatch situations. The results from these studies
ere inconsistent with the assumption of no protection made by
eed et al. [12].
In light of these ﬁndings, our research aims to model the cost-
ffectiveness of the various inﬂuenza vaccine options available to
S seniors (deﬁned herein as individuals 65 years of age or older).
ore speciﬁcally, we examine the public health impact, budget
mpact, and cost utility of HD versus IIV3 and IIV4 for the immu-
ization of US seniors.
. Methods
We  developed an economic model to explore the expected
mpact of vaccine on three primary health outcomes: symptomatic
nﬂuenza, inﬂuenza-associated hospitalizations, and inﬂuenza-
ssociated deaths. Impact on primary care medically attended
PCMA) inﬂuenza, Quality Adjusted Life Years (QALYs), and work
ays lost are contingent on each vaccine’s impact on the primary
utcomes. We  used a societal perspective and a 3% discount rate
17,18]. Costs and consequences are estimated over one inﬂuenza
eason, with the exception of premature deaths, which are cap-
ured beyond one season to include all QALYs lost until the life
xpectancy age. The epidemiology of the inﬂuenza season in our
tudy was reﬂective of average US epidemiology during 1999–2000
hrough 2008–2009.Our modeling strategy was based on estimating the impact of
ach vaccine as a function of vaccine efﬁcacy and uptake rates.
e started by calculating the rates of the primary outcomes in
n unvaccinated population of US seniors. For the incidence of (2015) 734–741 735
symptomatic inﬂuenza, we applied the attack rate of inﬂuenza
to this population [29]. For both hospitalizations and deaths, we
used historic US inﬂuenza-related outcome rates [1,2,34], vac-
cine coverage rates [29], and vaccine efﬁcacy estimates for the
general population to back calculate the incidence of inﬂuenza-
associated hospitalizations and deaths in an unvaccinated senior
population. This was  necessary because there are no published esti-
mates of the rates of hospitalization and death in unvaccinated
seniors. No herd effects were considered during this calcula-
tion.
Once the incidence rates were established in unvaccinated
seniors, we  stratiﬁed these rates in accordance with risk status.
Seniors were stratiﬁed into: high-risk (HR) or standard-risk (SR).
The HR group was  composed of seniors with co-morbidities that
increase the risk of inﬂuenza-related complications. The SR group
consisted of relatively healthy seniors without co-morbidities
and with relatively lower rates of inﬂuenza-related complica-
tions.
To explore the impact of each of the three vaccines (HD, IIV3,
and IIV4), we  ﬁrst established the efﬁcacy for each. The efﬁcacy
of IIV3 against symptomatic inﬂuenza was obtained from a meta-
analysis by Beyer and colleagues [14], while the relative efﬁcacy of
HD to IIV3 was  based on the FIM12 study (see online supplement
I) [49]. The absolute efﬁcacy of HD was therefore a function of the
absolute efﬁcacy of IIV3 and the relative efﬁcacy of HD to IIV3. We
estimated the vaccine efﬁcacy of IIV4 using a method similar to
that previously described by Reed and colleagues [12]. However, we
applied various adjustments in light of two  new ﬁndings on vaccine
efﬁcacy published subsequent to the article by Reed and colleagues
[12]. The ﬁrst ﬁnding was  by Beyer et al. [14] who estimated efﬁcacy
of IIV3 in seniors to be 28–49% which is lower than the 47–68%
used in the Reed publication. The second ﬁnding was reported by
two separate groups simultaneously, DiazGranados and colleagues
[15] and Tricco and colleagues [16], both estimating the efﬁcacy of
IIV3 against mismatched inﬂuenza B. These studies demonstrated
that IIV3 can provide protection against the alternate inﬂuenza B
lineage at a level approximating 60% of the matched efﬁcacy (see
online supplement II).
Next, we explored the expected impact of each of the three vac-
cine strategies (HD, IIV3, and IIV4) separately. Loss in Quality of
Life (QoL) was associated with experiencing any of the primary
health outcomes [29–32]. For cases of inﬂuenza-related death, the
model accounted for all lost QALYs from time of death until the
life expectancy age. The model then aggregated the changes in
QoL and computed differences in QALYs generated by the various
interventions.
The model accounted for costs of vaccine (both price and
administration fees), PCMA inﬂuenza, and inﬂuenza-related hos-
pitalizations [4,33–36]. We used the CMS  vaccine price and not
prices charged to other smaller segments of the market such
as US older adults who don’t qualify for CMS  coverage and US
older adults covered by the Veteran’s Affairs. We ignored these
as it was  judged that the impact of including them will have an
insigniﬁcant effect on the price (their weighted contribution is
insigniﬁcant). No health care costs were associated with deaths as
it was assumed that a hospitalization leading up to death would
be captured in the rate of inﬂuenza-related hospitalizations. Work
loss was  assumed to occur amongst employed seniors experiencing
symptomatic inﬂuenza, an inﬂuenza-associated hospitalization, or
an inﬂuenza-related death (limited to 90 days post-death). To
calculate lost productivity costs to employers, the model mul-
tiplied the average daily employer labor cost for working US
seniors by the number of days taken off work due to their illness
[20,30,32].
A few conservative assumptions were made in the model. Firstly,
indirect protection from vaccine to other individuals was  not taken
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nto account. Secondly, presenteeism due to inﬂuenza illness was
ot considered, as we could not identify data to quantify this effect.
inally, the model did not account for long-term disability that
ould result from inﬂuenza complications.
Potential adverse effects of inﬂuenza vaccination were not rep-
esented in the model. These generally involve mild-to-moderate
njection-site or systemic effects that are transient with negligible
ost and little impact on quality of life [50].
Online supplement III provides a visual illustration of the model.
able 1 summarizes all the model inputs. Online supplement IV
rovides further details on the model input selection.
able 1
nput values and sources.
Input Mean 
Population characteristics (US seniors ≥65 years)
Total population 41,506,000 
Employment rate 0.17 
Proportion of HRt 0.42 
Vaccine coverage 0.67 
Inﬂuenza attack ratea 0.057
Probability of ﬂu-related GPs consult
SRu 0.62 
HRt 0.82 
Flu hospitalization rate (per 100,000)c 297.92 
RRv ﬂu hospitalization HRt vs. SRu 3.80
Flu mortality rate (per 100,000)e 71.59 
RRv ﬂu mortality in HRt vs. SRu 8.33 
RRv ﬂu mortality in a given age group vs. 65–69 year old group
65–69 years old (reference) 1.00
70–74 years old 1.78
75–79  years old 3.53
80–84 years old 6.98
85–90 years old 19.35
90+  years old 19.35
Quality of life
Mean population utilities
65–69 years old 0.82
70–74 years old 0.78
75–79 years old 0.78
80–84 years olds 0.75
85+  years old 0.74
Uncomplicated ﬂu utility 0.25 
Flu hospitalization utility 0.20 
Time costs (days)
Duration of uncomplicated ﬂu symptoms 6.0 
Duration of ﬂu hospitalization 8.3 
Work time lost to uncomplicated ﬂu 1.9 
Work time lost to ﬂu hospitalization 8.3 
Monetary costs (USD)
Outpatient consultation (80% reimbursement) 111.86 
Medication cost (societal only) 8.58 
Hospitalization
SRu 11,914 
HRt 12,715 
Hospitalization co-payment 1184 
Daily labor 289.6 
Vaccine (USD per dose)
IIV3w 12.39 
HDx 32.82 
IIV4y 19.41 
Administration 25.86 
Vaccine effectiveness (%)
IIV3w
Against symptomatic inﬂuenza 49.00 
Against ﬂu-associated hospitalization 28.00 
Against ﬂu-associated death 28.00 
IIV4y,k
Against symptomatic inﬂuenza 50.68 
Against ﬂu-associated hospitalization 29.33 
Against ﬂu-associated death 28.87  (2015) 734–741
3. Results
3.1. Outcomes and costs
A shift from an IIV3 to a HD program would prevent an additional
195,958 cases of inﬂuenza, 22,567 inﬂuenza-related hospitaliza-
tions, and 5423 inﬂuenza-related deaths. The shift would require a
$568 million annual increase in the inﬂuenza immunization bud-
get while employers and medical services budgets would annually
be reduced by $116 million and $282 million respectively. The net
budget impact in the US would be $154 million.
95% CIq DSAr range Source
NA NA [26]
NA NA [27]
0.39–0.45 0.39–0.45 [28]
NA NA [29]
0.045–0.072 0.01–0.10b [30–32]
0.57–0.67 0.57–0.67 [33]
0.64–1.00 0.64–1.00 [33]
186.00–1103.70 186.00–1103.70d [1]
NA NA [28]
44.25–98.94 8.00–1211.00f [2–34]
NA NA [35]
NA NA [35]
NA NA [36]
NA 0.00–0.25 [37]
NA 0.00–0.25 [37]
NA 4–12 [38]
NA 5–10 [39]
NA 1–5 [37]
NA NA [39]
NA 101–119 [40,41]
NA NA [42]
11,010–12,817 11,009–12,817 [43]
11,703–13,727 11,703–13,727 [43]
NA NA [40]
NA NA [27]
NA 10.69–13.08 [40]
NA NA [40]
NA NA [40]
NA NA [40]
33.00–62.00 34.00–62.00 [14]
26.00–30.00 10.00–50.00g [14,21,44] h
26.00–30.00 10.00–50.00i [14] j
34.13–64.13 10.00–70.00 [12,14,33] l
27.24–31.43 10.00–60.00 [1,12,14,33] l
26.81–30.93 10.00–60.00 [2,12,14,33] l
A. Chit et al. / Vaccine 33 (2015) 734–741 737
Table  1 (Continued)
Input Mean 95% CIq DSAr range Source
HDx (relative effectiveness vs. IIV3)
Against symptomatic inﬂuenza 24.24 9.69–36.52 10.00–37.00m [49]
Against ﬂu-associated hospitalization 31.00 10.00–47.00 10.00–47.00n [49]
Against ﬂu-associated death 31.00 10.00–47.00 10.00–47.00o p
Discount rate (%) 3.00 NA 0–5 [18]
a Inﬂuenza attack rate estimated from placebo arms of the 3 referenced RCTs.
b Range selected based on review of historic US data on attack rate.
c Inﬂuenza hospitalization rates representing the period 1999–2008.
d Range selected based on 95% CI.
e Inﬂuenza mortality rates representing the period 1999–2008.
f Range selected based on lowest and highest rates of inﬂuenza-related mortality reported between 1979 and 2007.
g Range selected based on a review of vaccine effectiveness reported in referenced publications.
h Beyer et al. vaccine effectiveness values corroborated by the two referenced vaccine effectiveness publications.
i Range selected based on a review of vaccine effectiveness reported in referenced publications.
j Due to limited vaccine effectiveness studies against inﬂuenza mortality similar values were selected for this parameter as vaccine effectiveness against hospitalizations.
k No direct data are available for the vaccine effectiveness of IIV4.
l Vaccine effectiveness estimated based on data from the following sources.
m Range selected based on 95% CI.
n Range selected based on 95% CI.
o Range selected based on 95% CI.
p FIM12 was  not powered to investigate this variable, thus we  assumed protection to be the same as that offered against hospitalizations.
q CI: conﬁdence interval.
r DSA: deterministic sensitivity analysis.
s GP: general practitioner.
t HR: high-risk.
u SR: standard-risk.
v RR: relative risk.
w IIV3: trivalent standard-dose inﬂuenza vaccine.
x
1
t
$
g
s
i
p
3
r
t
p
t
t
a
$
T
IHD: trivalent high-dose inﬂuenza vaccine.
y IIV4: quadrivalent standard-dose inﬂuenza vaccine.
A shift from an IIV4 to a HD program would prevent an additional
69,257 cases of inﬂuenza, 21,222 inﬂuenza-related hospitaliza-
ions, and 5212 inﬂuenza-related deaths. The shift would require a
373 million annual increase in the inﬂuenza immunization bud-
et while employers and medical services budgets would annually
ave $110 million and $265 million respectively. The net budget
mpact in the US would be savings of $17 million. Tables 2 and 3
rovide further details.
.2. Incremental cost-effectiveness
From a societal perspective, the incremental cost effectiveness
atio (ICER) of an HD program versus an IIV3 program is expected
o be $5299/QALY. When restricting the analysis to a third party
ayer perspective (to only include costs to the health care system),
he ICER increases to $10,350/QALY. From a societal perspective
he HD program dominates the IIV4 program. When restricting the
nalysis to a third party payer perspective, the ICER increases to
4365/QALY.
able 2
mpact of various immunization strategies (no vaccine, HD, IIV3, and IIV4) on health outc
Outcomes No
vaccination
IIV3a IIV4b HDc
Total number of cases 2,365,842 1,589,134 1,562,433 1,393
Total  number of outpatient
consultations
1,665,080 1,118,433 1,099,641 980,5
Total  number of
hospitalizations
150,909 122,598 121,253 100,0
Total  number of deaths 36,263 29,460 29,249 24,03
Total  number of workdays lost 4,226,034 3,327,419 3,298,054 2,745
Total  number of QALYsd 205,939,572 205,980,642 205,981,947 206,0
a IIV3: trivalent standard-dose inﬂuenza vaccine.
b IIV4: quadrivalent standard-dose inﬂuenza vaccine.
c HD: trivalent high-dose inﬂuenza vaccine.
d QALY: Quality Adjusted Life Year.3.3. Incremental cost-effectiveness analysis of multiple
interventions
All three vaccines were compared with a reference point of no
vaccination program. Compared to no vaccine, HD had an ICER of
$8833/QALY; this was lower than ICERs computed for IIV3 vs. no
vaccine and IIV4 vs. no vaccine ($11,331/QALY and $15,001/QALY,
respectively). Fig. 1 and Table 4 provide a summary of these results.
3.4. Sensitivity analyses
Fig. 2 summarizes the univariate deterministic sensitivity anal-
ysis conducted on our model. The cost-effectiveness ratios are most
sensitive to the inﬂuenza-related death and hospitalization rates.
The next two most inﬂuential parameters are HD’s relative efﬁcacy
against hospitalization and death. However, all univariate deter-
ministic sensitivity analyses lead to ICERs below $100,000/QALY
gained, which is a commonly cited valuation for a QALY in the US
[50–54]. Data is scarce on trivalent vaccine protection against mis-
matched inﬂuenza B in seniors. As such, in a scenario analysis we
omes.
IIV3a vs. no
vacc
IIV4b vs. no
vacc
HDc vs. no
vacc
HDc vs.
IIV3a
HDc vs.
IIV4b
,177 −776,708 −803,409 −972,665 −195,958 −169,257
18 −546,647 −565,439 −684,562 −137,915 −119,123
31 −28,311 −29,656 −50,878 −22,567 −21,222
7 −6803 −7014 −12,226 −5423 −5212
,614 −898,615 −927,981 −1,480,422 −581,806 −552,441
09,666 41,070 42,375 70,094 29,023 27,718
738 A. Chit et al. / Vaccine 33 (2015) 734–741
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Fig. 1. Cost-effectiveness frontier. The incremental cost-effectiveness of the various
options (IIV3, IIV4 and HD) were simultaneously compared. The reference point is
no  vaccination. HD: trivalent high-dose inﬂuenza vaccine, IIV3: trivalent standard-
dose inﬂuenza vaccine, IIV4: quadrivalent standard-dose inﬂuenza vaccine, QALY:
Quality Adjusted Life Year.
did not allow trivalent vaccine to provide protection against mis-
matched inﬂuenza B (assuming that only IIV4 can protect against
these mismatches). This resulted in a modeled IIV4 efﬁcacy of 53.4%,
31.6%, and 30.3% against inﬂuenza symptoms, hospitalization and
death respectively. This did not result in a notable change in the
ICER and HD continued to dominate IIV4.
Fig. 2 also displays the results of our probabilistic sensitivity
analysis (PSA) of HD vs. IIV3 and HD vs. IIV4. The probability that
HD dominates IIV3 (more effective than IIV3 while less costly)
is 29%. The probability that HD will be at least cost-effective
compared to IIV3 ranges from 60% to 71%, for QALY valuations
of $50,000–$100,000 per QALY respectively. The probability that
HD dominates IIV4 (more effective than IIV4 while less costly) is
39%. The probability that HD will be at least cost-effective com-
pared to IIV4 ranges from 70% to 81%, for QALY valuations of
$50,000–$100,000 per QALY respectively.
Further sensitivity analysis on severity of inﬂuenza season and
HD price are summarized in online supplements VI and VII. HD
yielded ICERs below 100,000/QALY even under extreme assump-
tions around these variables.
4. Discussion
Our analysis has demonstrated that HD is a cost-effective alter-
native to both IIV3 and IIV4 for the immunization of US seniors. In
assessing the economic efﬁciency of the inﬂuenza vaccine program,
we conducted an incremental analysis of the three vaccine options
to no vaccine. This analysis revealed that even though an HD pro-
gram was the most expensive, it generated the most health (29,023
and 27,718 more QALYs than IIV3 and IIV4, respectively). Further,
compared to no program, HD had the lowest ICER ($8833/QALY)
and thus was  economically more efﬁcient than IIV3 or IIV4 pro-
grams.
An HD program for seniors would be also more cost-effective
than many other vaccine programs recommended by the US
CDC’s Advisory Committee on Immunization Practices and funded
by Medicare. For instance, the ICERs for other senior immu-
nization programs covered by Medicare such as herpes zoster
vaccine (ICER range: $27,000–$112,000/QALY); pneumococcal con-
jugate vaccine (ICER: $62,056/QALY); and tetanus toxoid, reduced
diphtheria toxoid and acellular pertussis vaccine (ICER range:
$13,000/QALY–$332,218/QALY), are all higher than what we have
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Table  4
Incremental cost-effectiveness analysis.
Intervention Total cost per person (USD) Total QALYsd per person Incremental cost (USD) Incremental QALYsd ICERe vs. no vaccination (USD/QALYd)
No vaccination 70.52 4.9617 – – –
IIV3a 81.73 4.96267 11.21 0.0010 Dominated
IIV4b 85.83 4.96270 4.10 0.00003 Dominated
HDc 85.43 4.9634 −0.40 0.0007 8833
a IIV3: trivalent standard-dose inﬂuenza vaccine.
b IIV4: quadrivalent standard-dose inﬂuenza vaccine.
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Rc HD: trivalent high-dose inﬂuenza vaccine.
d QALY: Quality Adjusted Life Year.
e ICER: incremental cost-effectiveness ratio.
stimated for the HD program [45–47,51]. The relative economic
alue of an HD immunization program is further realized when
ompared to other routinely recommended and funded prevention
rograms in the US. Maciosek and colleagues conducted a System-
tic Review of the cost-effectiveness of such programs [48]. Out of
5 programs only 5 would be more cost-effective than a HD pro-
ram. Collectively, this indicates that an HD immunization program
ill be a more efﬁcient use of health care resources than most pre-
entive programs and should be an implementation priority for US
ealth care policy makers.
The major strength of our study is that it relies on rela-
ive vaccine efﬁcacy estimates from study FIM12 [49]. The trial
nrolled approximately 32,000 seniors over 2 seasons and was
ble to investigate a number of exploratory endpoints beyond its
ig. 2. Sensitivity analysis on the cost-utility modes for: HD vs. IIV3 (panel A) and HD v
nalyses, and the cost-effectiveness acceptability curves, and (ii) depict the probabilisti
accine, HR: high-risk, IIV3: trivalent standard-dose inﬂuenza vaccine, IIV4: quadrivalen
VE:  relative vaccine efﬁcacy, VE: vaccine efﬁcacyprimary outcome. These included the relative efﬁcacy of HD against
inﬂuenza-related hospitalizations. It is reassuring to directly utilize
this high quality empirical evidence.
There are several limitations to our study. Firstly, the literature
that deﬁnes inﬂuenza vaccine efﬁcacy in seniors against outcomes
relevant to our model is restrictive in multiple ways. Though there
is evidence of vaccine efﬁcacy in seniors [14,20,21], the efﬁcacy data
were mainly derived from non-randomized studies that could be
prone to bias. There are also no empirical efﬁcacy data for IIV4 in
seniors against clinically and economically relevant outcomes. To
estimate efﬁcacy of IIV4, we  used a modiﬁed approach of the one
used by Reed and colleagues [12].
The second limitation of our model is that we did not account for
any impact of the vaccines on transmission dynamics. This ignores
s. IIV4 (panel B). Tornado diagrams: (i) depict univariate deterministic sensitivity
c sensitivity analyses. GP: general practitioner, HD: trivalent high-dose inﬂuenza
t standard-dose inﬂuenza vaccine, LR: low-risk, QALY: Quality Adjusted Life Year,
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ny indirect beneﬁt of the vaccines. Seniors are not considered to be
rivers of transmission [22], and it is generally accepted to discount
erd effects of senior vaccination programs.
Thirdly, we did not capture the impact of inﬂuenza vaccination
n disability. Work by McElhaney and colleagues [23] has argued
hat inﬂuenza vaccination has a signiﬁcant role in reducing the bur-
en of disability amongst seniors. Not modeling vaccine impact on
isability, while conservative, could be undervaluing the beneﬁts
f HD.
While there have been no estimates of the cost-utility of our par-
icular comparisons, it is appropriate to discuss the comparability
f our outcomes estimates to recent work by CDC researchers. Kos-
ova and colleagues from the CDC developed a model to forecast the
rotection afforded by vaccination against health outcomes similar
o ours [24,25]. Our estimates are within the range of those esti-
ated by CDC (online supplement V provides a comparison to our
ndings).
The cost-effectiveness of HD was robust against a PSA which
rew on the collective statistical parameter uncertainty in our
odel. The two most inﬂuential variables identiﬁed through uni-
ariate sensitivity analysis were rates of inﬂuenza-related death
nd hospitalization. Thus, the economic beneﬁts of HD are depend-
nt on the severity of the underlying inﬂuenza season. We
onducted a two-way sensitivity analysis on the two aforemen-
ioned variables to explore the impact of an unusually mild or
evere inﬂuenza season on the cost-utility of HD (see online sup-
lement VI for results). Even during an unusually mild inﬂuenza
eason, all of the simulated ICERs were below $100,000/QALY. IIV3
nd IIV4 were dominated by HD during unusually severe seasons.
In conclusion, HD is expected to achieve signiﬁcant reduc-
ions in inﬂuenza related morbidity and mortality. Further, HD is
xpected to be a cost effective alternative to both IIV3 and IIV4
n seniors. Our conclusions were robust in the face of sensitivity
nalyses. From an economic perspective, HD is a highly attractive
ption to replace IIV3 and IIV4 for immunization of US seniors.
Funding: The study was sponsored and funded by Sanoﬁ Pasteur.
ppendix A. Supplementary data
Supplementary data associated with this article can be
ound, in the online version, at http://dx.doi.org/10.1016/j.vaccine.
014.10.079.
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